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Abstract
Aim of these revised recommendations for the general management of Kawasaki disease is to encourage its
prompter recognition and warrant the most appropriate therapy, based on ascertained scientific data, raising
awareness of the complications related to misdiagnosis or delayed treatment. A set of 20 synthetic operative
statements is herein provided, including the definition of Kawasaki disease, its protean presentations, clinical course
and seminal treatment modalities of all disease phases. The application of these recommendations should improve
prognosis of Kawasaki disease and prevent the progression to permanent vascular abnormalities, thereby
diminishing morbidity and mortality.
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Background
Two years after the diffusion of the Italian Guidelines
for diagnosis and treatment of Kawasaki disease (KD),
we have updated 20 operative recommendations focus-
ing on the general management of this widespread ill-
ness of unknown etiology, which mostly occurs in
infants and children under 5 years of age with risk of
heart implications, especially if the diagnosis is missed
or if timely appropriate treatment is overlooked [1, 2].
First described in Japan in l967 by Tomisaku Kawasaki,
the disease occurs in children of all ethnicities and is
one of the leading cause of acquired cardiovascular dis-
ease in the pediatric age [3]. The basic symptom of KD
is persistently high and nonresponding fever, despite
antipyretic and antibiotic treatments [4]. Japan, Korea
and Taiwan are the countries with the highest frequency
of KD, reflecting a potential genetic susceptibility among
the Asian populations. In addition, the age distribution
of KD, higher in children less than 2 years and lower in
those less than 6 months, is consistent with a potentially
infectious disease, though KD has been even reported in
newborns [5, 6].
The identification of the causing mechanisms behind
KD would be essential to develop preventive strategies
or focused therapies, but the definite etiology remains
elusive. A number of theories have linked KD to bac-
teria, viruses and different environmental factors, but
none has been proved. It is discussed if the trigger of
KD might be an RNA virus that normally causes an
asymptomatic infection in most children and KD in a
subset of genetically predisposed children [7]. The most
significant complications in KD are cardiovascular and
prominently involve coronary arteries, though the overall
incidence of coronary artery abnormalities (CAA) has
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: rolando.cimaz@unimi.it
4Pediatric Rheumatology, ASST Gaetano Pini-CTO, Milan, Italy
5University of Milan, Milan, Italy
Full list of author information is available at the end of the article
Marchesi et al. Italian Journal of Pediatrics           (2021) 47:16 
https://doi.org/10.1186/s13052-021-00962-4
been reduced by treatment with intravenous immuno-
globulin (IVIG) given within 7–10 days after disease on-
set [8]. Diagnosis of KD is clinical, supported by the
results of labworks and imaging, but no findings or test
can be considered highly specific. Diagnostic difficulties
depend also on the different presenting times of signs
and symptoms, the gruelling identification of other in-
fectious and non-infectious illnesses mimicking KD, the
occurrence of non-typical manifestations and incomplete
patterns of the disease [9, 10].
Aim of these synthetically revised recommendations is
suggesting the best practice for the management of chil-
dren with KD, based on the most recent scientific
evidence.
Definitions of Kawasaki disease
Typical KD
Typical KD is characterized by fever lasting at least 5
days combined with at least 4 among 5 main clinical fea-
tures (clinical criteria):
[a] bilateral non-exudative conjunctivitis,
[b] anomalies of the lips and oral mucosa (redding and
cracking of lips, strawberry tongue, pharyngeal
hyperemia),
[c] anomalies of the extremities (redding of palms and
soles, indurative edema of hands and feet) and perineal
region,
[d] polymorphous exanthema,
[e] acute nonpurulent cervical lymphadenopathy (usu-
ally unilateral and larger than 1,5 cm).
The suspicion of KD may be initially cumbersome, as
clinical features do not appear at the same time [11].
The presence of fever is universal and fever onset is con-
sidered the first day of the illness, though the diagnosis
of KD should be considered also in children in whom
fever has subsided before the 5th day [12].
The 2017 American Heart Association guidelines sug-
gest that in the presence of more than 4 main clinical
features, particularly when the child shows redness and
swelling of hands and feet, the diagnosis can be estab-
lished with only 4 days of fever. They also claim that ex-
perienced clinicians who have treated many KD patients
could establish a diagnosis even with only 3 days of fever
in the presence of classic clinical features [13].
The decision to hospitalize or discharge children with
fever lasting around 5 days might depend on the educa-
tional and socioeconomic status of their families or the
availability of community medical services [14]. Several
children may have incomplete or atypical forms of KD
and discrimination of such forms from infections and
other febrile conditions of childhood is an arduous chal-
lenge even for an experienced pediatrician: scholastically,
incomplete KD should be considered in case of children
with unexplained fever for more than 5 days associated
with 2 or 3 classic features, while atypical KD in case of
children with unexplained fever for more than 5 days as-
sociated with non-classic clinical signs which do not re-
spond to a proper therapy. The most fearful
complications of KD are CAA, which develop in 15-to-
25% of non-treated patients, but only in 5% of those
properly treated, and are normally detected by echocar-
diography [13].
Recommendation 1
Typical KD is diagnosed when fever lasting more than 5
days is associated with ≥ 4 clinical criteria (bilateral non-
exudative conjunctivitis, changes of lips and oral mu-
cosa, changes of the extremities and perineal region,
polymorphous exanthema and cervical lymphadenop-
athy); in the case of CAA early demonstrated on echo-
cardiography diagnosis of KD is possible also when a 4-
day-lasting fever is associated with the known criteria.
Incomplete KD
The medical literature has been recently enriched by in-
creasing reports of incomplete KD, mostly in children
younger than 12months, and this should be suspected in
every infant showing fever for more than 5 days with docu-
mented systemic inflammation in terms of increased C-
reactive protein (CRP) and white blood cell count [15–17].
The diagnosis of incomplete KD is suggested if less than 4
main clinical features are found after exclusion of many fe-
brile illnesses. In a 2-year nationwide survey (counting
more than 23.000 children with incomplete KD) 3, 2 and 1
of the main clinical features were met in 26.6, 6.1 and 0.7%
of cases, respectively [18].
Recommendation 2
Incomplete KD can be diagnosed when fever lasting
more than 5 days is associated with 2 or 3 clinical cri-
teria, with or without CAA.
Atypical KD
Atypical KD occurs in children with a classic fever pat-
tern combined with further different non-classic signs,
including aseptic meningitis, seizures, peripheral facial
nerve palsy, sensorineural hearing loss, gallbladder
hydrops, jaundice, acute abdomen, pancreatitis, arthritis,
renal injury, orchitis, pneumonia, sterile pyuria, with or
without CAA [17, 19].
Recommendation 3
Atypical KD is diagnosed when fever lasting more than
5 days, not otherwise explained, is combined with non-
classic manifestations nonresponsive to standard treat-
ments, with or without CAA.
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The clinical course of Kawasaki disease
KD clinical course can be divided into three phases:
(a) acute (1st-2nd week), in which diagnosis should be
established and treatment started,
(b) subacute (3rd-4th week), characterized by deferves-
cence, periungual skin desquamation, thrombocytosis
and eventual formation of CAA,
(c) convalescence phase (5th–8th week), in which all
KD signs disappear, inflammatory markers subside to
normal and nail indentations (Beau’s lines) may appear.
Child’s extreme irritability is characteristic during the
acute phase of KD [20].
Investigations in Kawasaki disease
Diagnosis of KD should be considered in all children dis-
playing fever for 5 days (or more), as prognosis relies on a
prompt treatment. Consequently, in case of suspected KD,
it is important to recommend patient’s hospitalization.
Unfortunately, laboratory tests are nonspecific for KD,
though leukocytosis, anemia and elevation of acute-phase
reactants, such as CRP, can support the diagnosis in com-
bination with classic features [21, 22]. Hypoalbuminemia
is common and associated with more severe and more
prolonged acute disease. Urinalysis may show pyuria in up
to 80% of children. Additional helpful findings are elevated
levels of brain natriuretic peptide (BNP) and N-terminal
pro-BNP. Thrombocytosis is characteristic during the sub-
acute phase, peaking in the third week and normalizing 4-
to-6 weeks after onset. Thrombocytopenia is rare, but may
occur in the first 1–2 weeks of illness: it can be a sign of
disseminated intravascular coagulation or macrophage ac-
tivation syndrome (MAS) and is a risk factor for the devel-
opment of CAA [23].
Recommendation 4
Abnormal laboratory parameters (mostly the elevation of
C-reactive protein) can only support the diagnosis of KD
in febrile patients with evocative clinical features.
Treatment of Kawasaki disease
Intravenous immunoglobulin
The main goal of treatment in the acute phase of KD is
suppressing systemic inflammation and minimizing the
risk of developing CAA. Administration of IVIG is over-
all recognized as the “first-line” treatment for KD both
in terms of efficacy and safety [24]. In particular, high-
dose IVIG (2 g/kg of body weight in a single infusion)
significantly reduces the incidence of CAA and over-
throws both inflammation and fever, as shown by a sys-
tematic Cochrane review: IVIG is indicated in typical,
incomplete and atypical KD [25]. IVIG infusion should
be performed in 10–12 h if patient’s cardiac function is
normal or in 16–24 h for patients displaying cardiac fail-
ure. IVIG should be administered before the 10th day of
illness, best if before the 7th day since onset, as CAA
might appear starting from the 8-9th day [26]. Treat-
ment before the 5th day of fever should be reserved to
exceptional cases of unequivocal diagnosis of KD [27].
IVIG should also be administered to children presenting
after the 10th day of illness in case of persistent fever or
ongoing systemic inflammation. Defervescence after
IVIG occurs usually within 48 h in about 80–85% of
cases. A reoccurring fever 36–48 h after a first adminis-
tration of IVIG configures the framework of IVIG-
resistant KD (this approximately occurs in 15–20% of
patients) [28]. Nowadays there is no universally accepted
treatment for these patients yet, and therefore the man-
agement of these cases should be established
individually.
Recommendation 5
IVIG at the dose of 2 g/kg of body weight is the treat-
ment of choice for KD, preferably given within the 10th
day, better if within the 7th day of illness, but as soon as
possible after diagnosis.
Aspirin
Treatment of KD is completed by adding aspirin (acetyl-
salicylic acid, ASA): medium-high dosage of ASA (from
80mg/kg/day, mostly in the USA, to 30–50 mg/kg/day
in Japan, UK and Europe, divided into 4 doses) is used
for its anti-inflammatory effect during the acute phase,
while 48 h after defervescence ASA can be switched to a
lower dosage (3–5 mg/kg/day in a single dose) due to its
anti-platelet effect. The overall duration of anti-platelet
treatment is 6–8 weeks in KD patients without CAA,
while it is maintained until the resolution of coronary le-
sions in patients with CAA [29]. Recent studies have also
suggested that ASA could be started immediately at the
anti-platelet dosage in the acute phase, though further
randomized clinical trials are required to compare the
efficacy of medium-high and low-dose aspirin [30].
Medium-high dose ASA should be replaced in case of
concurrent varicella or influenza to avoid the potential
development of Reye’s syndrome [31]. Conversely, low-
dose ASA has not been associated with the occurrence
of this syndrome: however, in case of symptoms or ex-
position to influenza or varicella, parents of children
with KD are asked to promptly contact their physician
[13]. Children may receive dipyridamole (1–5 mg/kg/day
divided into 3 doses), ticlopidine (2–7 mg/kg/day divided
into 2 doses) or clopidogrel (1 mg/kg/day in a single
dose up to a maximum of 75 mg/day in children > 2
years or 0.2 mg/kg of body weight in children < 24
months) in replacement of ASA, even if there is less ex-
perience with the use of these drugs. Ibuprofen (like
other nonsteroidal anti-inflammatory drugs involving
the cyclooxygenase pathway) antagonizes the anti-
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platelet effect of low-dose ASA and usually should be
avoided in children on anti-platelet ASA [13]. If ibupro-
fen or similar drugs are needed, alternative anti-platelet
therapies (e.g. clopidogrel) should be considered.
Recommendation 6
Treatment of KD is completed by ASA given at a daily
dosage of 30–50mg/kg in the acute phase of KD until
48 h after the disappearance of fever, then switched to
the anti-platelet dose (3–5 mg/kg once daily).
Recommendation 7
Low-dose ASA must be continued until 6-to-8 weeks in
children without CAA and continued in children with
CAA until the resolution of coronary artery lesions.
Recurrence of Kawasaki disease
Recurrence of KD ranges from 1.4 to 3% of cases, and
symptoms are often the same as for the first episode.
IVIG resistance, the elevation of liver enzymes and re-
duced hemoglobin level are risk factors for the recur-
rence of KD. In addition, recurrent forms of KD can be
associated with a higher incidence of CAA [32]. Recur-
rent KD requires the same treatment as used for the first
episode. Hereditary autoinflammatory syndromes need
to be considered for a comprehensive differential diag-
nosis of recurrent KD in childhood [33–35].
Non-responsiveness of Kawasaki disease
Resistant KD is defined by failure to respond to IVIG
therapy and consists in a recrudescent fever 36–48 h
after IVIG infusion [36]. It is believed that IVIG-
resistant KD reflects severity of the underlying inflam-
mation, explaining the increased incidence of CAA in
this subset of patients. Severe anemia at disease onset,
early development of CAA, and signs of MAS or septic
shock should be considered in predicting the risk of
IVIG non-responsiveness [37]. The identification of pa-
tients with KD having a higher propensity to be IVIG-
refractory is challenging: many efforts have been made
to discriminate which patients might not respond to
IVIG in order to undertake a more aggressive treatment
combined with IVIG, but different scores useful in the
Eastern Asiatic populations have been unsuccessful in
the Caucasians [21, 38–40].
Recommendation 8
Resistant KD is defined by failure in the response to
IVIG and is revealed by recrudescent fever reoccurring
or persisting 36–48 h after IVIG infusion.
Treatment of resistant forms of Kawasaki disease
Several second-line treatment options are available for
resistant KD, which are represented by an additional
IVIG infusion, intravenous methylprednisolone pulses,
infliximab and other biologic drugs. Randomized con-
trolled trials evaluating the effectiveness of these differ-
ent options apart from the second infusion of IVIG are
poor [41].
Corticosteroids
Most vasculitides are treated with corticosteroids due to
their immunosuppressive and anti-inflammatory proper-
ties [42]. The use of corticosteroids as second-line treat-
ment in KD has been hugely debated, because of
differences among studies (all patients versus high-risk
patients, Eastern Asiatic versus Caucasian populations).
Intravenous pulses of methylprednisolone at the dose of
30 mg/kg of body weight can be provided as second-line
treatment for resistant KD patients [43, 44]. Indeed,
non-responder patients with KD should be managed
with a second IVIG cycle and - in case of failure - with 3
pulses of methylprednisolone (30 mg/kg/day), followed
by oral prednisone (2 mg/kg/day, then gradually tapered
up to the resolution of symptoms and normalization of
CRP). Following the observation that methylpredniso-
lone added to the standard regimen of IVIG improved
outcomes of coronary arteries in Japanese patients with
severe KD [45], “high-risk” patients, i.e. children less
than 12months or those having CRP higher than 200
mg/l, severe anemia at disease onset, albumin level
below 2.5 g/dl, liver disease, overt coronary artery aneu-
rysms, macrophage activation syndrome or septic shock,
may require an initial therapy with IVIG (plus ASA) in
combination with an intravenous pulse of methylpred-
nisolone (30 mg/kg/day). When these KD patients fail to
respond to such scheme, a second IVIG cycle combined
with further 3 pulses of methylprednisolone (30 mg/kg/
day) plus ASA should be given, followed by prednisone
at the initial dose of 2 mg/kg/day, then tapered up to the
resolution of symptoms and normalization of CRP.
Recommendation 9
In non-responder patients with KD treatment requires a
second infusion of IVIG and - in case of failure - pulses
of methylprednisolone (30 mg/kg/day) for 3 consecutive
days, followed by oral prednisone (2 mg/kg/day, then
gradually tapered).
Recommendation 10
In high-risk patients with KD initial treatment should
include:
– IVIG + single intravenous pulse of
methylprednisolone (30 mg/kg/day) + low-dose
aspirin (3–5 mg/kg/day).
– In case of failure treatment should be implemented
with a further infusion of IVIG and three pulses of
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intravenous methylprednisolone (30 mg/kg/day,
followed by prednisone: 2 mg/kg/day, then gradually
tapered) + low-dose aspirin (3–5 mg/kg/day).
Biological drugs
Biologics may target the presumed key-cytokines in-
volved in KD pathogenesis, namely tumor necrosis factor
(TNF)-α and interleukin (IL)-1 [46, 47]. Many consider-
ations about their use are derived from the experience
with anti-TNF or anti-IL-1 drugs on small series of KD
patients. Current evidence supports the use of inflixi-
mab, a chimeric monoclonal antibody against TNF-α, as
rescue therapy at a single intravenous dose of 5 mg/kg of
body weight (given in 2 h) for IVIG- and corticosteroid-
resistant KD patients. However, no trials have evaluated
its use as adjunctive therapy in patients with early evi-
dence of CAA [48]. There are studies confirming the ef-
fectiveness of anakinra, the recombinant IL-1 receptor
antagonist blocking the natural biological activity of IL-
1, in children with a refractory KD, given subcutaneously
at a daily dose of 4–8 mg/kg of body weight for an over-
all period of 15 days or for a longer period, depending
on the specific clinical scenery. Anakinra might also pre-
vent the development of CAA [49]. The use of canakinu-
mab, a high-affinity human monoclonal antibody targeted
against IL-1β (using a single subcutaneous injection of 4
mg/kg/dose) may be also a future option for cases of
IVIG-resistant and corticosteroid-resistant KD [50, 51].
Recommendation 11
Current evidence supports the use of infliximab as res-
cue therapy in IVIG- and methylprednisolone-refractory
patients with KD; IL-1 blockade with anakinra is highly
promising in treating the most dramatically severe
multi-refractory patients with KD, with potential benefits
also on the cardiovascular complications.
We have summarized the therapeutic recommenda-
tions for patients with KD (Fig. 1) and for those who
should be defined as “high-risk” patients (Fig. 2).
Complications of Kawasaki disease
The most relevant risk for children with KD is the devel-
opment of vascular abnormalities, affecting small-to-mid
size arteries, but characteristically the coronary arteries.
Fig. 1 General Treatment of patients with KD
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A coronary artery anomaly may start as ectasia, progress
to moderate dilatation (5-to-8 mm of diameter) until the
formation of large aneurysms (measuring more than 8
mm). A standardized classification to measure coronary
arteries and characterize CAA, comparing vessel diame-
ters to the body surface area and measuring the standard
deviation from the average in z units, is listed in Table 1
[52]. This classification is recommended for the right
coronary, left anterior descending and left main coron-
ary arteries, and z-scores with reference values for
pediatric echocardiography are available at the website
www.parameterz.com.
Coronary artery involvement is virtually absent if the
z-score is < 2 and present if the z-score is beyond 2. Pa-
tients with giant aneurysms (having z-scores ≥10) display
the highest risk of both coronary thrombosis and sten-
osis [53]. Other cardiovascular complications include
myocarditis, pericarditis, myopericarditis, valvular le-
sions, arrhythmias, heart failure in addition to coronary
thrombosis or stenosis and myocardial infarction [54].
Pneumonia, encephalitis, seizures, paralytic ileus, chole-
cystitis, liver dysfunction, cholecystitis, anemia, hypoal-
buminemia, electrolyte imbalance, diarrhea, vomiting
and dehydration might occur in KD, and specific treat-
ments may be required [19]. Other severe non-
cardiovascular complications are MAS, largely known to
occur in a host of disorders characterized by hypercyto-
kinemia, heralded by non-remitting fever, impaired liver
function, hyperferritinemia, hypertriglyceridemia,
Fig. 2 Treatment of High-Risk patients with KD. (children less than 12 months or children having C-reactive protein higher than 200mg/l, severe
anemia at disease onset, albumin level below 2.5 g/dl, liver disease, overt coronary artery aneurysms, macrophage activation syndrome or
septic shock)
Table 1 Classification of coronary artery abnormalities in the
acute phase of Kawasaki disease
No coronary artery involvement: z-score < 2
Dilatation of the coronary artery: z-score > 2 to < 2.5 SD
Small aneurysm of the coronary artery: z-score≥ 2.5 to < 5 SD
Medium aneurysm of the coronary artery: z-score≥ 5 to < 10 SD
Giant aneurysm of the coronary artery: z-score≥ 10 SD
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hypofibrinogenemia, pancytopenia and frequently hemo-
phagocytosis [55, 56], and KD-related shock syndrome,
associated with hypotension, platelet consumption and
increased risk of CAA [57].
Evaluation of the cardiovascular involvement in
Kawasaki disease
KD vasculitis involves a variety of blood vessels and, in
particular, small muscular arteries, being caused by dif-
fuse neutrophil infiltration with necrotizing features,
which might potentially lead to vessel dilatation mostly
occurring during the subacute phase [58]. In general
terms, CAA may start as ectasia which might regress
within 8 weeks in most cases [59]. The regression of
small or medium coronary aneurysms might occur
within 1–2 years after onset, but large and giant aneu-
rysms may persist over a long time due to local fibrosis
and calcifications, with the risk of acute coronary syn-
drome [60]. Non-responsiveness to IVIG is a crucial sign
to define KD severity, as these children have the highest
risk of developing CAA [61]. Additionally, CAA are
most prevalent in patients having incomplete KD [62].
Recommendation 12
The most relevant complications in KD are cardiovascu-
lar sequelae starting as CAA, which are more frequently
disclosed during the subacute phase of the disease.
The role of echocardiography
Bidimensional and color-Doppler echocardiography
must be performed when KD diagnosis is suspected,
then after 2, 4 and 8 weeks in the non-complicated cases
by cardiologists experienced in pediatrics [63]. However,
it is important to ensure that the timing or results of the
echocardiogram should not delay the initial treatment of
KD during the acute phase. An initial echocardiogram in
the first week of illness is typically normal and does not
rule out KD diagnosis. The uncooperative irritable child
may require sedation; if this is not possible, a further as-
sessment should be repeated as soon as possible within
48 h after diagnosis. The coronary artery imaging should
include the left main coronary artery, left anterior de-
scending, left circumflex, right coronary artery (prox-
imal, middle and distal segments), and posterior
descending coronary artery. In patients with evolving
CAA, follow-up assessments with echocardiography
should be performed more frequently to monitor even-
tual increases in vessel dimensions and the potential
presence of thrombosis.
Recommendation 13
Echocardiography is pivotal for the diagnosis of coronary
artery involvement in children with KD and should be
periodically repeated 2, 4 and 8 weeks after onset in the
uncomplicated cases.
The role of other imaging techniques
Advanced techniques for the assessment of KD-related
cardiovascular sequelae are computed tomography (CT)
and magnetic resonance (MR) angiography [64]. CT
scan should be used to confirm CAA, define size and
morphology of CAA, identify thrombosis or occlusions,
and evaluate other aneurysms, both central or periph-
eral, in the whole body, but its use is limited by exten-
sive radiation exposure [65]. Cardiovascular MR
angiography with gadolinium-based contrast often re-
quires the use of general anesthesia in younger patients
and can be used to confirm CAA, investigate other cen-
tral or peripheral anuerysms, identify biventricular sys-
tolic function, detect areas of inducible myocardial
ischemia during pharmacological stress and evaluate
myocardial scars [66].
Recommendation 14
Cardiovascular CT scan and MR angiography, where
available, are important to assess persistent CAA in chil-
dren with KD and monitor remodeling of either coron-
ary or systemic arteries in the whole body.
Treatment of the cardiovascular complications of
Kawasaki disease
Long-term therapy in KD patients with CAA aims at
preventing the cardiovascular acute events with reduc-
tion of both incidence and severity of acute coronary
syndrome. Such therapy depends on the features and ex-
tension of CAA. In the absence of “evidence-based” stud-
ies, recommendations have been drafted by pediatric
retrospective studies. Platelet activation is critical in all
KD phases, therefore, in case of persistent CAA, chronic
use of anti-platelet low-dose ASA (3–5mg/kg/day) must
be provided, optionally associated with other anti-platelet
and/or anticoagulant and/or anti-angina drugs, according
to the size of aneurysms, flow characteristics, and presence
or absence of myocardial ischemic changes [67].
Supplementary anti-platelet drugs
Persistent structural multiple or complex coronary artery
aneurysms may require dual anti-platelet prophylaxis,
based on low-dose ASA and clopidogrel. There is still
insufficient data on the use of clopidogrel, an ADP-
P2Y12 receptor inhibitor, in infants and children, for
whom anti-platelet response might be different. Anti-
platelet action of clopidogrel is usually achieved with
lower doses (0.2 mg/kg/day) in children aged < 24
months, while older children may require higher doses
(up to 1 mg/kg/day): light transmission platelet aggrego-
metry is a common method to assess platelet function
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in vitro for patients using clopidogrel, though universal
standards are lacking [68]. Clopidogrel may be also a
valid alternative to ASA in case of ASA intolerance or
resistance, varicella (either the wild type disease or vac-
cination against varicella) and influenza [69].
Recommendation 15
KD patients with medium-sized coronary artery aneu-
rysms or those with multiple and complex aneurysms re-
quire dual anti-platelet prophylaxis, based on low-dose
ASA (at a single dose of 3–5 mg/kg/day) and clopidogrel
(at a single dose of 0.2 mg/kg/day in children aged < 24
months and up to 1mg/kg/day in children aged ≥ 24
months).
Anticoagulant drugs
Anticoagulants are indicated in the case of giant aneu-
rysms, coronary thrombosis or history of acute myocar-
dial ischemia. Warfarin (0.05–0.12 mg/kg/day once daily,
carefully adjusting the dose until reaching an inter-
national normalized ratio, INR, between 2.0 and 3.0) is
the most widely used drug for long-term anticoagulation
[70]. The use of low-molecular weight heparin (LMWH)
can be considered in infants with KD for whom a regular
assessment of INR is troublesome. In particular, enoxa-
parin (100 IU/kg/dose every 12 h) is a LMWH with dem-
onstrated safety and efficacy, frequently used in
pediatrics as a bridging anticoagulant regimen with low
risk of thromboembolism and low risk of bleeding com-
plications [71]. Fondaparinux, an antithrombin-
dependent selective inhibitor of factor Xa, is not ap-
proved for use in children. However, in comparison to
LMWH, fondaparinux has several properties which
make it attractive, including a longer half-life, lack of ef-
fects on bone metabolism and reduced risk of heparin-
induced thrombocytopenia. Fondaparinux (at a single
daily dose of 0.1 mg/kg of body weight) has been admin-
istered to children with deep venous thrombosis without
severe adverse events [72]. Novel oral anticoagulants do
not require routine laboratory assessment, but there are
very few data about their employment in pediatrics.
Recommendation 16
It is reasonable to treat KD patients having complex or
severe CAA with low-dose ASA associated with warfarin
(keeping INR targeted at 2.0–3.0) or LMWH (if regular
INR checking is difficult). Triple therapy with ASA, war-
farin or LMWH and clopidogrel should be considered in
KD patients with a relevant risk of thrombosis.
Non-invasive treatment of coronary artery
thrombosis
Patients with giant aneurysms of coronary arteries are at
higher risk of presenting thrombosis and developing
acute coronary syndrome. The goal of treatment in KD
patients who show coronary thrombosis is to restore
flow patency, preserve the myocardial tissue and increase
patient’s survival [73]. Thrombolytic treatment with
tissue-type plasminogen activator is the most commonly
administered therapeutic regimen in treating fresh
thrombosis within medium/large or giant coronary an-
eurysms. A multidisciplinary approach is needed to
optimize outcome of KD patients receiving thrombolysis,
that should be performed by experienced interventional
radiologists or cardiologists in intensive care setting to
allow rapid intervention in the case of bleeding. The
ability to quickly obtain coagulation testing results for
ongoing adjustments of therapy is critical for managing
patients who require thrombolysis and concomitant
anticoagulation. The most relevant thrombolytic drug in
young patients with KD complicated by coronary artery
thrombosis is the intravenous recombinant tissue plas-
minogen activator (rtPA), and in recent years “alteplase”
has become the most widely used in children. Fresh fro-
zen plasma (10–20ml/kg) given before using rtPA works
as a plasminogen source. Various dosing regimens have
been compared, but high doses of alteplase (0.5 mg/kg,
10% infused over 1–2 min and the remainder over 60
min) are more commonly used [74]. A careful monitor-
ing of coagulation testing every 6–12 h is mandatory to
prevent bleeding (maintaining the fibrinogen level > 100
mg/dl and platelet count > 50,000/mm3). Low-dose
thrombolytic therapy may be also associated with abcixi-
mab, a glycoprotein IIb/IIIa inhibitor, given intraven-
ously (as a bolus of 0.25 mg/kg in 30 min, then followed
by 0.125 μg/kg/minute, max: 10 μg/min, for 12 h) in the
case of thrombosis with high risk of forthcoming vessel
occlusion [75, 76]. Both rtPA and abciximab require to
be associated with low-dose ASA and intravenous hep-
arin (10 U/kg/hour). Coronary thrombosis should be
reassessed with echocardiographic imaging during and
after completion of thrombolysis.
Recommendation 17
Recombinant tissue plasminogen activator (rtPA) is the
first-choice thrombolytic drug in children with KD com-
plicated by coronary artery thrombosis; the glycoprotein
IIb/IIIa inhibitor abciximab may be used in case of
thrombosis with high risk of occlusion. Both therapies
require a concomitant association with low-dose ASA
and intravenous heparin.
Invasive treatment of coronary artery thrombosis
Coronary artery reperfusion by both invasive cardiac
interventional procedures and cardiac surgery should be
considered after unsuccessful pharmacological thromb-
olysis or when stenotic lesions are eventually present in
selected patients. It is important to consult an adult
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interventional cardiologist and/or an adult cardiothor-
acic surgeon with experience in revascularization of pa-
tients with KD if revascularization is considered.
Cardiac procedures include intracoronary catheter-
directed thrombolysis, percutaneous balloon angioplasty
with or without coronary stenting and rotational ather-
ectomy with or without coronary stenting [77]. There is
no standard protocol or preferred device in pediatrics,
and the use of any of these modalities often relies on
physician’s experience. In order to determine the most
appropriate procedure it is desirable that physicians con-
sider patient’s body size, coronary angiography findings
and intravascular ultrasound. Invasive treatment should
be considered in patients with or without ischemic
symptoms caused by coronary artery stenosis (≥75% of
the luminal diameter), but with instrumentally demon-
strated ischemia (via stress electrocardiogram or stress
perfusion imaging) [78]. Coronary angioplasty procedure
has a risk of vessel re-stenosis and occlusion, requiring
the use of stenting or alternative procedures, such as
coronary artery bypass grafting or percutaneous translu-
minal rotational ablation [79]. Heart transplantation can
be proposed in selected cases with irreversible myocar-
dial dysfunction [80].
Recommendation 18
First-choice cardiologic interventional treatment in pa-
tients with KD should be chosen in the shortest time
based on the specific experience of a pediatric cardiac
surgery team.
Follow-up of patients with Kawasaki disease
Patients with KD must undergo regular cardiologic eval-
uations with electrocardiogram and echocardiography in
the long-term. For patients with large coronary aneu-
rysms diagnosed in the first months after disease onset it
is recommended to perform echocardiography weekly
[81]. Cardiologic evaluations performed in the convales-
cence phase allow to subdivide KD patients according to
their cardiovascular impairment into different risk clas-
ses and establish a personalized follow-up protocol. It is
reasonable to consider KD patients worthy of close mon-
itoring for their cardiovascular risk, evaluating and con-
trolling blood pressure, body mass index, blood lipid
profile and promoting correct lifestyles [82]. Cardiologic
assessment allows to consider 5 different risk classes ac-
cording to the cardiovascular sequelae and establish a
personalized follow-up protocol (Table 2) [1, 2, 13].
Recommendation 19
Cardiologic assessments allow to split KD patients into
different risk classes according to the cardiovascular se-
quelae and establish a personalized follow-up protocol.
Vaccinations in children with Kawasaki disease
Treatment of KD with IVIG does not significantly inter-
fere with inactivated vaccines, oral attenuated live virus
vaccines, live virus nasal vaccines, bacillus Calmette-
Guérin vaccine or yellow fever vaccine. Subsequently,
these vaccines can be safely administered at any time
after IVIG administration. Conversely, it is recom-
mended to wait 10–12months before administration of
vaccines against measles, mumps, rubella (MMR), vari-
cella (V) and MMRV, as IVIG administration might re-
sult in reduced immunogenicity and interfere specifically
with the immune response of these live attenuated vac-
cines. A seasonal inactivated influenza vaccine is recom-
mended in children with KD receiving ASA [83].
Recommendation 20
All inactivated vaccines can be safely administered at
any time after IVIG in KD patients. Attenuated live virus
vaccines (MMR, V and MMRV vaccines) should be ad-
ministered 10–12months after the administration of
IVIG to avoid a reduced specific immune response in
KD patients; influenza vaccination is recommended in
KD patients receiving ASA.
A relationship with the SARS-CoV-2 pandemic
threat with Kawasaki disease?
During the 2020 pandemic caused by the novel corona-
virus (SARS-CoV-2) infection a number of severely ill
patients with a systemic inflammatory syndrome, which
has been named “pediatric multisystem inflammatory
syndrome temporally associated with coronavirus disease
(COVID-19) or PIMS-TS” in the UK and “multisystem
inflammatory syndrome associated with COVID-19 or
MIS-C” in the USA, have been reported. The pathogen-
esis of this multisystem syndrome is rather unclear,
though some overlapping features suggesting an
immune-mediated vasculitis like KD have been de-
scribed: the inflammatory response in this condition dif-
fers from KD with respect to cell subsets involved and
biomarkers associated with vascular damage [84]. There
has been a huge debate about the substantial risk that
first-line providers encountering febrile patients might
miss or delay the diagnosis of KD and proper treatment
with IVIG. While there are no definite proofs of a rela-
tionship between SARS-CoV2 and KD, it is important to
remind a high suspicion level for KD in all children with
prolonged fever, mostly those younger than 12 months,
and to perform echocardiograms to monitor eventual
cardiovascular complications in these little patients even
after a confirmed infection by SARS-CoV-2 [85].
Final remarks
This list of 20 revised recommendations, drafted 3 years
after the American Heart Association Statement and 2
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years after the publication of the Italian Guidelines for
diagnosis and treatment of KD, summarizes the most
relevant clues to manage KD patients, highlighting rele-
vant points for both clinicians and researchers. Their
aim is spreading the best practice in general manage-
ment of children with such a complex disorder, so that
long-term morbidity and potential mortality might be
prevented across the life span. We have herein refined
the definition of cardiovascular and systemic complica-
tions of KD, recurrent forms of KD and treatment mo-
dalities with corticosteroids or biological agents in
refractory patients. Treatment of cardiovascular compli-
cations with anti-platelet drugs and/or anticoagulants
and treatment of coronary artery thrombosis with both
pharmacological and non-pharmacological approaches
have been also discussed. Every clinical decision-making
should be specifically tailored on the individual patient
with KD.
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